Dr. Dunbar is interested in atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of nicotinic acid (niacin). He has developed sophisticated objective techniques to quantify the physical stigmata of flushing from niacin. He combines these techniques with laboratory pharmacodynamic studies to elucidate the integrated physiology of the response to niacin.
Dr. Dunbar specializes in the treatment of cholesterol disorders, and practices in the Preventive Cardiology Clinic at the Pereleman Center for Advanced Medicine
Selected Publications
Usman HU, Qamar A, Gadi R, Lilly S, Goel H, Hampson J, Mucksavage M, Nathanson GA, Rader DJ, Dunbar RL: Extended-Release Niacin Acutely Suppresses Postprandial Triglyceridemia Am.J.Med. 125(10), October 2012.
Usman MHU, Nakaya K, Qamar A, Gadi R, Nathanson GA, Nijjar P, Wolfe M, Rader DJ, Dunbar RL: Single-Dose Extended-Release Niacin Acutely Attenuates HDL Reduction in the Setting of Experimental Oral Fat Challenge: A Possible Role of ANGPTL-3 and CETP Modulation [Oral Presentation] ATVB 32, April 2012 Notes: Arteriosclerosis, Thrombosis, and Vascular Biology 2012 Scientific Sessions, Chicago, IL.
Lauring B, Taggart AK, Tata JR, Dunbar RL, Caro L, Cheng K, Chin J, Colletti SL, Cote J, Khalilieh S, Liu J, Luo W, MacLean AA, Peterson LB, Polis AB, Sirah W, Wu T, Liu X, Jin L, Wu K, Boatman PD, Semple G, Behan DP, Connolly DT, Lai E, Wagner JA, Wright SD, Cuffie C, Yale MB, Rader DJ, Paolini JF, Waters MG, Plump A
: Niacin Lipid Efficacy is Independent of both the Niacin Receptor GPR109A and Free Fatty Acid Suppression. Sci.Transl.Med. 126, 2012.
deGoma EM, French B, Dunbar RL, Allison MA, Mohler, ER, Budoff MJ: Intraindividual variability of C-reactive protein: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 224, 2012.
The AIM-HIGH Investigators: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. NEJM 11 2011.
AIM-HIGH Investigators: The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am.Heart J 161(3): 471-7, 3 2011.
The AIM-HIGH Investigators: The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am.Heart J 161(3): 538-543, 3 2011.
Dunbar RL, Gelfand JM: Seeing red: flushing out instigators of niacin-associated skin toxicity. J.Clin.Invest 120(8): 2651-5, August 2010.
Burke MF, Dunbar RL, Rader DJ: Could exercise metabolomics pave the way for gymnomimetics? Sci.Transl.Med. 2(41): 1-3, July 2010.
Dunbar R, Gadi R, Baer A, Goel H, Baber A, Rehan M, Rader D, Millar J: Fenofibric and Nicotinic Acid Progressively Suppress Postprandial Triglyceridemia in Statin-Treated Patients with Low High-Density Lipoprotein Cholesterol [Oral Presentation] J Am Coll Cardiol March 2010 Notes: 59th American College of Cardiology Scientific Conference, Atlanta, GA, March, 2010.
back to top
Last updated: 08/22/2012
The Trustees of the University of Pennsylvania
